PCM
ABBV icon

Polaris Capital Management’s AbbVie ABBV Stock Holding History

Polaris Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9M Sell
71,264
-45,413
-39% -$9.77M 1.69% 25
2026
Q1 		$25.4M Sell
116,677
-3,100
-3% -$688K 2.08% 25
2025
Q4 		$27.4M Sell
119,777
-22,167
-16% -$5.05M 2.27% 20
2025
Q3 		$32.9M Sell
141,944
-10,700
-7% -$2.18M 2.16% 20
2025
Q2 		$28.3M Sell
152,644
-11,000
-7% -$2.04M 1.89% 27
2025
Q1 		$34.3M Sell
163,644
-64,235
-28% -$12.5M 1.96% 18
2024
Q4 		$40.5M Sell
227,879
-7,500
-3% -$1.38M 1.95% 14
2024
Q3 		$46.5M Buy
235,379
+900
+0.4% +$168K 2.29% 10
2024
Q2 		$40.2M Sell
234,479
-3,800
-2% -$629K 2.16% 15
2024
Q1 		$43.4M Sell
238,279
-57,800
-20% -$9.96M 2.16% 12
2023
Q4 		$45.9M Sell
296,079
-7,900
-3% -$1.15M 2.22% 9
2023
Q3 		$45.3M Sell
303,979
-115,037
-27% -$16.9M 2.44% 6
2023
Q2 		$56.5M Sell
419,016
-1,542
-0.4% -$226K 2.12% 15
2023
Q1 		$67M Hold
420,558
– – 2.5% 6
2022
Q4 		$68M Sell
420,558
-1,000
-0.2% -$153K 2.37% 8
2022
Q3 		$56.6M Sell
421,558
-7,557
-2% -$1.08M 2.22% 10
2022
Q2 		$65.7M Sell
429,115
-32,300
-7% -$4.94M 2.35% 7
2022
Q1 		$74.8M Sell
461,415
-23,000
-5% -$3.34M 2.38% 7
2021
Q4 		$65.6M Sell
484,415
-700
-0.1% -$82.7K 2.12% 16
2021
Q3 		$52.3M Buy
485,115
+60,300
+14% +$6.89M 1.67% 25
2021
Q2 		$47.9M Buy
424,815
+5,100
+1% +$574K 1.54% 30
2021
Q1 		$48.8M Sell
419,715
-30,600
-7% -$3.27M 1.6% 30
2020
Q4 		$48.3M Buy
450,315
+359,700
+397% +$34.6M 1.81% 22
2020
Q3 		$7.94M Sell
90,615
-316
-0.3% -$29.8K 0.39% 41
2020
Q2 		$8.93M Buy
+90,931
New +$8.01M 0.44% 41

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Polaris Capital Management's ABBV Position: Q2 2026 in Review

Polaris Capital Management reduced its AbbVie (ABBV) stake by 39% in Q2 2026, selling an estimated $9.77M and leaving 71,264 shares worth $17.9M. The position accounts for 1.69% of the portfolio, ranked #25.

Polaris Capital Management first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. The position peaked at $74.8M in Q1 2022. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Polaris Capital Management held 71,264 shares of AbbVie worth $17.9M as of Q2 2026.
  • Polaris Capital Management sold 45,413 AbbVie shares in Q2 2026, an estimated $9.77M.
  • AbbVie made up 1.69% of Polaris Capital Management's portfolio in Q2 2026, its #25 holding.
  • Polaris Capital Management first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • Polaris Capital Management's AbbVie position peaked at $74.8M in Q1 2022.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Polaris Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.